Self-register for coronavirus vaccine through govt's new Co-WIN App | All you need to know

New Delhi | Jagran News Desk: In a significant move in making the COVID-19 vaccine available to the general public, the government recently launched an app named, 'Co-WIN App', through which the users will be able to self-register for the coronavirus vaccine. Those who will be pre-registered on the app will get the vaccine at the earliest as soon as any vaccination will be launched for use.

India has been considering early authorisation of three COVID-19 vaccine candidates including the Pfizer-BioNTech, SII's COVIDHIELD and indigenously prepared Bharat Biotech's COVAXIN. 

Co-WIN is an upgraded version of the Electronic Vaccine Intelligence Network (eVIN) and available to download for free on the Play Store. In the first two stages, the government will vaccinate priority groups including frontline workers and emergency workers. People with co-morbidities will get the jab in the third stage. For this, a self-registration process will be required through the Co-WIN app.

The Co-WIN app will have four modules for vaccinators, beneficiaries and administrators. These are - administrator module, registration module, vaccination module, beneficiary acknowledgement module and report module.

People who want to get vaccinated will have to apply and provide details under the registration module. In Vaccination module, their details will be verified and beneficiary acknowledgement module will send a certificate to them about their vaccination.

Hyderabad-based Bharat Biotech Monday said that it has applied for the emergency use authorisation of its coronavirus vaccine candidate Covaxin. Earlier, American pharma major Pfizer and the Serum Institute of India had applied to the central drug regulator for emergency use approval of their coronavirus vaccines.

However, the first two vaccines were developed by foreign countries but Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). The vaccine is still in the third stage of clinical trials.